CLSA Premium Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2023. For the period, the group expected to record an unaudited net profit of approximately HKD 5.2 million, as compared with the unaudited consolidated net loss of approximately HKD 17.5 million in the corresponding period of 2022. The expected net profit was mainly attributable to the combined effects of the following
factors: The growth of healthcare products business in the first half of 2023 with revenue from sales of healthcare products of approximately HKD 130 million for the six months ended 30 June 2023, as compared with the revenue of approximately HKD 8 million for the six months ended 30 June 2022; and the Group has continued to take actions to streamline operations and make the business more efficient, which has reduced expenses in the first half of 2023 as compared with the first half of 2022 including approximately HKD 7.6 million on the staff cost and approximately HKD 1.2 million on IT maintenance and support expenses.